Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 543.65M P/E - EPS this Y 31.70% Ern Qtrly Grth -
Income -233.98M Forward P/E -3.73 EPS next Y 17.10% 50D Avg Chg 12.00%
Sales 10.5M PEG - EPS past 5Y - 200D Avg Chg 36.00%
Dividend N/A Price/Book 2.03 EPS next 5Y - 52W High Chg -17.00%
Recommedations 1.80 Quick Ratio 18.19 Shares Outstanding 266.09M 52W Low Chg 96.00%
Insider Own 18.03% ROA -18.50% Shares Float 131.75M Beta 2.04
Inst Own 75.97% ROE -61.80% Shares Shorted/Prior 10.73M/12.42M Price 3.13
Gross Margin - Profit Margin - Avg. Volume 730,825 Target Price 10.40
Oper. Margin -1,839.25% Earnings Date Aug 8 Volume 386,508 Change -0.63%
About Autolus Therapeutics plc

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Autolus Therapeutics plc News
11/19/24 Autolus Therapeutics upgraded to Buy from Neutral at Goldman Sachs
11/15/24 Autolus Therapeutics Third Quarter 2024 Earnings: US$0.31 loss per share (vs US$0.26 loss in 3Q 2023)
11/15/24 Syncona Ltd (LSE:SYNC) Half Year 2025 Earnings Call Highlights: Navigating Market Challenges ...
11/13/24 Autolus Therapeutics PLC (AUTL) Q3 2024 Earnings Call Highlights: Strategic Advances and ...
11/13/24 Q3 2024 Autolus Therapeutics PLC Earnings Call
11/12/24 Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
11/11/24 These Stocks Moved the Most Today: Tesla, DJT, Coinbase, MARA, Cigna, Humana, AbbVie, Super Micro, and More
11/11/24 Autolus secures FDA approval for CAR-T cell therapy use in ALL
11/11/24 FDA approves new CAR-T competitor to Gilead’s Tecartus
11/08/24 Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
11/05/24 Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations
11/03/24 Further weakness as Autolus Therapeutics (NASDAQ:AUTL) drops 21% this week, taking five-year losses to 71%
10/28/24 Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
10/17/24 Autolus Therapeutics (AUTL): High-Growth UK Stock in Cancer Therapy
10/16/24 Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress
10/16/24 Why Autolus Therapeutics plc (AUTL) is the Penny Stock with the Biggest Upside Potential According to Analysts
10/09/24 Autolus Therapeutics PLC (AUTL) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ...
09/19/24 Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer
09/12/24 Autolus Therapeutics PLC (AUTL): Fast-Growing Penny Stock To Consider
09/01/24 Autolus Therapeutics plc (AUTL): The Best Multibagger Penny Stock of 2025?
AUTL Chatroom

User Image Trending__Now Posted - 3 hours ago

$AUTL I was listening to one of my podcasts and I can't remember who was chatting but it was some billionaire. He said he knows of companies getting ready for Mergers and Acquisitions once Trump takes office. Trump apparently plans on breaking down the barriers. Come January 20th or leading up to it we may have a little mini boom into summer.

User Image Mnpois Posted - 6 hours ago

$AUTL would love to see some open market CEO buys...

User Image gandolf63 Posted - 8 hours ago

$AUTL buy buy buy

User Image Mnpois Posted - 8 hours ago

$AUTL dark times indeed

User Image Dryrunner999 Posted - 10 hours ago

$AUTL swing low, sweet chariot

User Image Mnpois Posted - 10 hours ago

$AUTL someone buy this out already

User Image Mnpois Posted - 12 hours ago

$AUTL holding for SLE data in q1 2025. Added to my Mar $5 calls today

User Image gandolf63 Posted - 14 hours ago

$AUTL

User Image Mnpois Posted - 14 hours ago

$AUTL 2.5 cash per share with fda approved drug lmao. 75% tute ownership

User Image Trending__Now Posted - 14 hours ago

$AUTL Patience. Trading near cash value. Best in class from what we know. We buy on down days so another averaging down is an opportunity. Analysts are starting to notice and provide updates. Buys like this are rare and all we have to do is wait. Money will flow back in. At this price with all our cash, we might as well be bought out. Have a great week.

User Image gandolf63 Posted - 16 hours ago

$AUTL this shit shouuld be illegal

User Image Iceman89 Posted - 16 hours ago

$AUTL EOY tax loss selling

User Image gandolf63 Posted - 16 hours ago

$AUTL this is where they want it folks to load up

User Image Mnpois Posted - 16 hours ago

$AUTL someone hates this stock

User Image gandolf63 Posted - 16 hours ago

$AUTL seems like an offering patern

User Image Magic8BallResponse Posted - 17 hours ago

$AUTL What a DOG

User Image gandolf63 Posted - 17 hours ago

$AUTL new lows every day! with such a good thing going as the newly approved cancer drug its very strange how we go down every day. willing to buy more just not sure of bottom

User Image Mnpois Posted - 19 hours ago

$AUTL holding up nicely given shit market. $4 by Christmas

User Image gandolf63 Posted - 20 hours ago

$AUTL i think powers that be want this as low as possible. $2

User Image MR2601 Posted - 20 hours ago

$AUTL hold tight ;this is a temporary event.The SP shall go up with more than one positive catalyst in the horizon. Solid fundamental ,science ,FDA approved drug and great partners.Its gift at this price.

User Image Chachi88 Posted - 21 hours ago

$AUTL Let’s see what today brings…first leg up or more of the same?

User Image Mnpois Posted - 1 day ago

$AUTL market makers suppressing this stock with fake volume once they have their shares this will run

User Image funnymoney90210 Posted - 1 day ago

$AUTL

User Image Mnpois Posted - 1 day ago

$AUTL has $2.5 cash per share…

User Image Mnpois Posted - 1 day ago

$BFLY risk it for the biscuit $AUTL 👀

User Image Mnpois Posted - 1 day ago

$AUTL market is sleeping on this

User Image rubraquercus Posted - 1 day ago

$AUTL The “more tolerable” safety profile of Autolus’ option, however, stands to make the therapy the preferred option for ALL patients and eventually support majority market share, the analysts added. In the FELIX study, the treatment showed low levels of cytokine release syndrome (CRS) with 3% grade 3 events and no grade 4 or 5 events. https://www.fiercepharma.com/pharma/autolus-readies-its-aucatzyl-car-t-go-after-heavy-hitter-competition-after-landing-fda

User Image Mnpois Posted - 1 day ago

$IOVA new kid on the block: $AUTL

User Image Mnpois Posted - 1 day ago

$AUTL 11/19/24 "Goldman Sachs upgraded Autolus Therapeutics (AUTL) to Buy from Neutral with a price target of $7.60, up from $7. The recent approval of lead asset Aucatzyl represents a de-risking event for the company’s technology platform and manufacturing facilities and the label granted by the FDA supports Aucatzyl’s differentiated safety profile, contends the firm, which sees “a significant dislocation between the company’s fundamental valuation and current market value.”"

User Image Mnpois Posted - 1 day ago

$BFLY keep flying $AUTL time will come

Analyst Ratings
Needham Buy Jun 17, 24
Needham Buy Jun 3, 24
Needham Buy May 17, 24
Needham Buy Apr 12, 24
Truist Securities Buy Apr 9, 24
Truist Securities Buy Mar 18, 24
Needham Buy Mar 14, 24
Needham Buy Feb 12, 24
Needham Buy Jan 22, 24